Literature DB >> 15168731

Antigenic differences between metastatic cells in bone marrow and primary tumours and the anti-MUC1 humoral immune response induced in breast cancer patients.

M V Croce1, M Isla-Larrain, R Tur, M E Rabassa, A Segal-Eiras.   

Abstract

The dissemination of a malignant neoplasia is a complex process, which requires a set of molecules that remains unknown. It has been suggested that mucins and their carbohydrate-associated antigens may be implicated in tumour spreading which may be also influenced by an anti-MUC1 immune response. In this pilot study, we report the pattern of carbohydrate and peptidic MUC1-associated epitopes on carcinoma cells isolated from bone marrow (BM), taking into account primary tumour histopathologic features. We also bring information about the anti-MUC1 humoral response in these patients. Seventeen patients with invasive breast carcinoma were included. A sample of the primary tumour, a serum sample and a BM aspirate were obtained from each patient. Clinical features studied were tumour size, number of metastatic nodes, histological type and disease stage. Standard immunohistochemistry was performed with antigenic retrieval using different monoclonal antibodies (MAbs): anti carbohydrate antigens: Lewis x (KM380), sLewis x (KM93), Lewis y (C14) and Tn, anti-MUC1 peptide core MAbs: C595, HMFG2 and SM3, anti-cytokeratins, anti-protoncogenes ErbB2 and ErbB3 (IgG) MAbs and also anti-CD34 and anti-CD45 MAbs. ELISA techniques were employed to study circulating MUC1 as well as free and complexed anti-MUC1 antibodies. Immunohistochemical results showed that carbohydrate antigenic expression increases in BM neoplastic cells compared to the original tumours. However, we were not able to demonstrate that a humoral immune response to MUC1 has been induced in these patients. Finally, the employed procedures allow the selective immortalisation of micrometastatic carcinoma cells since short-term cell lines were established.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15168731     DOI: 10.1023/b:clin.0000024739.43297.ba

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  50 in total

1.  Survival in early breast cancer patients is favorably influenced by a natural humoral immune response to polymorphic epithelial mucin.

Authors:  S von Mensdorff-Pouilly; A A Verstraeten; P Kenemans; F G Snijdewint; A Kok; G J Van Kamp; M A Paul; P J Van Diest; S Meijer; J Hilgers
Journal:  J Clin Oncol       Date:  2000-02       Impact factor: 44.544

2.  Increased level of circulating adhesion molecules in the sera of breast cancer patients with distant metastases.

Authors:  N Matsuura; T Narita; C Mitsuoka; N Kimura; R Kannagi; T Imai; H Funahashi; H Takagi
Journal:  Jpn J Clin Oncol       Date:  1997-06       Impact factor: 3.019

3.  Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status.

Authors:  I J Diel; M Kaufmann; S D Costa; R Holle; G von Minckwitz; E F Solomayer; S Kaul; G Bastert
Journal:  J Natl Cancer Inst       Date:  1996-11-20       Impact factor: 13.506

4.  Specific, major histocompatibility complex-unrestricted recognition of tumor-associated mucins by human cytotoxic T cells.

Authors:  D L Barnd; M S Lan; R S Metzgar; O J Finn
Journal:  Proc Natl Acad Sci U S A       Date:  1989-09       Impact factor: 11.205

5.  Outcome of primary-breast-cancer patients with micrometastases: a long-term follow-up study.

Authors:  J L Mansi; H Gogas; J M Bliss; J C Gazet; U Berger; R C Coombes
Journal:  Lancet       Date:  1999-07-17       Impact factor: 79.321

6.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.

Authors:  D J Slamon; W Godolphin; L A Jones; J A Holt; S G Wong; D E Keith; W J Levin; S G Stuart; J Udove; A Ullrich
Journal:  Science       Date:  1989-05-12       Impact factor: 47.728

7.  Detection of micrometastatic tumor cells in bone marrow of breast carcinoma patients.

Authors:  S E Singletary; L Larry; S L Tucker; G Spitzer
Journal:  J Surg Oncol       Date:  1991-05       Impact factor: 3.454

Review 8.  MUC1, the renaissance molecule.

Authors:  S J Gendler
Journal:  J Mammary Gland Biol Neoplasia       Date:  2001-07       Impact factor: 2.698

9.  Episialin (MUC1) overexpression inhibits integrin-mediated cell adhesion to extracellular matrix components.

Authors:  J Wesseling; S W van der Valk; H L Vos; A Sonnenberg; J Hilkens
Journal:  J Cell Biol       Date:  1995-04       Impact factor: 10.539

10.  Expression of alpha-GalNAc glycoproteins by breast cancers.

Authors:  S A Brooks; A J Leathem
Journal:  Br J Cancer       Date:  1995-05       Impact factor: 7.640

View more
  2 in total

1.  Transmembrane mucins as novel therapeutic targets.

Authors:  Pamela E Constantinou; Brian P Danysh; Neeraja Dharmaraj; Daniel D Carson
Journal:  Expert Rev Endocrinol Metab       Date:  2011-11

2.  Sialylated Lewis x antigen bearing glycoproteins in human plasma.

Authors:  Wonryeon Cho; Kwanyoung Jung; Fred E Regnier
Journal:  J Proteome Res       Date:  2010-10-11       Impact factor: 4.466

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.